If the cells you would like to access are currently listed as unavailable or you are ordering from outside of Europe please get in touch via Contact@EBiSC.org.

SIGi001-A-16

SIGi001-A-9 Bi-Allelic MAPT HA-tag

Gene-edited iPSC line

Not-for-profit fee: £1700 per vial
Immediately available for distribution*
*Once all legal and processing details completed
Timepoint: Confluency
Magnification: 4x
Timepoint: Confluency
Magnification: 10x
A CLIP contains information about a cell line including any specific third party obligations relating to, for example, licensing obligations or the donor consent which affect the use of the cell line.

The EBiSC Access and Use Agreement must be completed along with an individual Cell Line Information Pack for each line. Complete the EAUA and send to Contact@EBiSC.org for countersignature. The EAUA must be fully signed before proceeding with your order.
A batch specific Certificate of Analysis will be available to download once you receive your EBiSC iPSC line.

General#

Cell Line

hPSCreg name SIGi001-A-16
Alternative name(s)
SIGi001-A-9 Bi-Allelic MAPT HA-tag
Cell line type Human induced pluripotent stem cell (hiPSC)
Similar lines
SIGi001-A-3
(iPSC0028 MAPT P301L C4)
SIGi001-A-4
(iPSC0028 MAPT P301L D4)
SIGi001-A-5
(iPSC0028 MAPT P301S 1C9C4)
SIGi001-A-6
(iPSC0028 MAPT P301S 1B9C9)
SIGi001-A-7
(iPSC0028 MAPT P301S 2G2B7)
SIGi001-A-12
(iPSC0028 - BiAllelic MAPT_Ex10+16T/Clone 1F5-D12, SAMEA104237570)
SIGi001-A-8
(iPSC0028 MAPT P301S+Ex10+16/Clone 7D11A7)
SIGi001-A-9
(iPSC0028 MAPT P301S+Ex10+16/Clone 7H6A1)
SIGi001-A-10
(iPSC0028 MAPT P301S+Ex10+16/Clone 7G4A8)
SIGi001-A-11
(iPSC0028 MAPT P301S+Ex10+16/Clone 7C6A4, SAMEA4451118)
SIGi001-A-13
(iPSC0028 – MonoAllelic MAPT_Ex10+16T/Clone 1D01-11)
SIGi001-A-1
(iPSC0028 SLC17A7/GFP E3)
SIGi001-A-2
(iPSC0028 SLC17A7/GFP C3)
SIGi001-A-14
(SIGi001-A Bi-Allelic MAPT HA-tag)
SIGi001-A-15
(SIGi001-A Dox inducible NGN2)
SIGi001-A-17
(SIGi001-A-9 Dox inducible NGN2)
SIGi001-A-18
(SIGi001-A-12 Bi-Allelic MAPT HA-tag #U28-12-P29-5)
SIGi001-A-19
(SIGi001-A-12 Dox inducible NGN2)
Notes SIGi001-A-9 (iPSC0028 MAPT P301S+Ex10+16/Clone 7H6A1) having a HA-tag at the C-terminal end of MAPT, Bi-Allelic

Provider

Depositor Bioneer (BION)
Owner Bioneer (BION)
Distributors
EBiSC

External Databases

hPSCreg SIGi001-A-16
BioSamples SAMEA6080815
Cellosaurus CVCL_A7GT
Wikidata Q107116926

General Information

This EBiSC line can be used for:
Yes
Research use: allowed
Clinical use: no
Commercial use: no
Subclone of (not in EBiSC, see SIGi001-A in hPSCreg)

Donor Information#

General Donor Information

Sex female
Ethnicity Caucasian

Phenotype and Disease related information (Donor)

Diseases No disease was diagnosed.
Family history no
Is the medical history available upon request? no
Is clinical information available? no

Other Genotyping (Donor)

Is there genome-wide genotyping or functional data available?
No

External Databases (Donor)

BioSamples SAMEA4447434

hIPSC Derivation#

General

More source cell information can be found in the parental cell line SIGi001-A in hPSCreg.
Passage number reprogrammed +15

Reprogramming method

Vector type Integrating
Vector Virus (Retrovirus)
Genes
Is the used vector excisable?
No
Absence of reprogramming vector(s)?
Unknown
Reprogramming vectors silenced?
Unknown

Vector free reprogramming

Other

Derived under xeno-free conditions
No
Derived under GMP?
No
Available as clinical grade?
No

Culture Conditions#

Latest released batch

Culture medium mTeSR1
Passage method Accutase
Surface coating Matrigel
O2 concentration 21
CO2 concentration 5
Temperature 37 °C
The following are the depositor culture conditions, they do not refer to any specific batch.
Surface coating Matrigel/Geltrex
Feeder cells
No
Passage method Enzymatically
Accutase
O2 Concentration 5 %
CO2 Concentration 5 %
Medium mTeSR™ 1
Has Rock inhibitor (Y27632) been used at passage previously with this cell line?
No
Has Rock inhibitor (Y27632) been used at cryo previously with this cell line?
No
Has Rock inhibitor (Y27632) been used at thaw previously with this cell line?
No

Characterisation#

Analysis of Undifferentiated Cells
Marker Expressed Immunostaining RT-PCR Flow Cytometry Enzymatic Assay Expression Profiles
POU5F1 (OCT-4)
Yes
SOX2
Yes
SSEA-4
Yes
TRA 1-81
Yes
SSEA-1
No
Morphology pictures
Differentiation Potency
Endoderm
Ont Id: UBERON_0000925
In vitro directed differentiation
Morphology
Mesoderm
Ont Id: UBERON_0000926
In vitro directed differentiation
Morphology
Ectoderm
Ont Id: UBERON_0000924
In vitro directed differentiation
Morphology

Microbiology / Virus Screening

HIV 1 Negative
HIV 2 Negative
Hepatitis B Negative
Hepatitis C Negative

Sterility

Inoculation for microbiological growth No Contaminants Detected
Mycoplasma Not Detected
Viability Viable post-cryopreservation

Genotyping#

Karyotyping (Cell Line)

Has the cell line karyotype been analysed?
Yes
46,XX
Passage number: +15
Karyotyping method: G-Banding

Other Genotyping (Cell Line)

Genetic Modification#

Disease/phenotype related modifications
Synonyms
  • Frontotemporal Dementia
Genetic modifications
MAPT (target)
Isogenic modification
17
NM_001203252
Homozygous
An HA-tag has been added to the endogenous MAPT gene. The MAPT gene has a P301S and an Exon 10 + 16 mutation (both homozygous)
An HA-tag has been added to the endogenous MAPT gene. The MAPT gene has a P301S and an Exon 10 + 16 mutation (both homozygous)